5 Furthermore, adults with obesity incurred higher medical costs than individuals with healthy weight
Here's what we'll cover Here's what we'll cover Here's what we'll cover Key takeaways Tirzepatide is the active ingredient in Mounjaro and Zepbound, two injectable medications that are prescribed for weight loss, type 2 diabetes, and obstructive sleep apnea
Some patients report positive experiences with quick turnaround and effective medication
In addition to weight loss, its important to review other health indicators like blood pressure, cholesterol levels, and A1C
SURMOUNT-1 showed mean systolic blood pressure reductions of up to 7.4 mmHg with the 15 mg dose over 72 weeks, alongside substantial weight loss averaging 1521% of baseline body weight
Current evidence suggests that most patients regain significant weight within one year of stopping semaglutide, indicating that this is likely a long-term or indefinite therapy for obesity management rather than a short-term intervention